Upadacitinib and secukinumab for PsA offers comparable improvements in skin and joint symptoms, but adalimumab offers superior pain relief.

Patients with IPF and emphysema who received antifibrotic agents had similar outcomes to patients with IPF alone.

The Food and Drug Administration has granted Breakthrough Therapy designation to CD388 for seasonal influenza prevention.

Results of an RCT showed that CBD 50 mg was not superior to placebo for reducing pain intensity among patients with fibromyalgia.

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

The ambient AI scribe improved clinician burnout, ability to provide undivided attention, and care note understandability.

The war in Congo has made it nearly impossible for supplies to reach medical clinics on both sides of the front line.

Direct-mail human papillomavirus self-test kits increased screening rates and were found to be cost-effective.

Patients with PsA who are treated with CTT are not at a greater risk for serious or opportunistic infections compared with standard therapy.

Results of a meta-analysis showed that a history of allergies, multiorgan involvement, and decreased complement levels were linked to higher risk for IgG4-RD relapse.

The Food and Drug Administration has approved Enoby, a biosimilar to Prolia, and Xtrenbo, a biosimilar to Xgeva.

Both medication-based and surgical weight loss interventions were linked to lower rates of obesity-related cancers in people with obesity and T2D.